Biomarkers /
ERBB2
Back to Biomarkers List
Overview
ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, also known as HER2 and neu) is a gene that encodes for the receptor tyrosine-protein kinase erbB-2. ERBB2 has been found to be amplified with an increased copy number in several cancers (PMID: 20185938). Amplification of ERBB2 promotes tumorigenesis and pathogenesis of several human cancers (PMID: 17471238). Recently, in breast cancer patients without ERBB2 gene amplification, activating ERBB2 mutations have also been identified (PMID: 23220880).
ERBB2 is altered in 4.98% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, and invasive breast carcinoma having the greatest prevalence of alterations [3].
The most common alterations in ERBB2 are ERBB2 Mutation (2.63%), ERBB2 Amplification (3.30%), ERBB2 Exon 20 Mutation (0.55%), ERBB2 Exon 20 Insertion (0.34%), and ERBB2 S310F (0.31%) [3].
Biomarker-Directed Therapies
ERBB2 is a predictive biomarker for use of trastuzumab, fulvestrant, aromatase inhibitor, lapatinib, pertuzumab, ado-trastuzumab emtansine, everolimus, abemaciclib, capecitabine, endocrine therapy, alpelisib, cisplatin, docetaxel, exemestane, letrozole, paclitaxel, palbociclib, ribociclib, anastrozole, atezolizumab, carboplatin, fam-trastuzumab deruxtecan, fluorouracil, margetuximab, nab-paclitaxel, neratinib, pembrolizumab, pertuzumab/trastuzumab/hyaluronidase, sacituzumab govitecan, tamoxifen, trastuzumab/hyaluronidase, and tucatinib in patients.
Breast carcinoma, adenocarcinoma of the gastroesophageal junction, gastric carcinoma, malignant salivary gland neoplasm, and colorectal carcinoma have the most therapies with ERBB2 as a predictive biomarker.
Of the therapies with ERBB2 as a predictive biomarker, 23 are FDA-approved in at least one clinical setting and 25 have NCCN guidelines in at least one clinical setting.
ERBB2 Amplification, ERBB2 Loss, ERBB2 L755S, ERBB2 Y772_A775dup, and ERBB2 V777L are the top alterations on ERBB2 targeted by therapies [4].
Abemaciclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. |
Ado-Trastuzumab Emtansine +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated (as a single agent) for the treatment of patients with HER2+ positive breast cancer in either the adjuvant or metastatic setting who previously received trastuzumab and a taxane, separately or in combination. |
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN-recommended for HER2+ salivary gland tumors. |
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN. |
Everolimus +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Fam-Trastuzumab Deruxtecan +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting |
Lapatinib +
Breast Carcinoma -
Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Neoadjuvant (BNF) |
Margetuximab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated in combination with chemotherapy for metastatic HER2-positive breast cancer that received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. |
Neratinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2-positive breast cancer, both in combination with capecitabine for advanced or metastatic disease with two or more prior anti-HER2 based regimens in the metastatic setting, and as a single agent for extended adjuvant treatment following adjuvant trastuzumab-based therapy. |
Pembrolizumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10]. |
Pertuzumab +
Pertuzumab/trastuzumab/hyaluronidase +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, pertuzumab/trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab + pertuzumab in any regimen. |
Sacituzumab Govitecan +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. |
Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2-overexpressing breast cancer: (1) for metastatic disease with paclitaxel as first-line treatment, and as a single agent after one or more chemotherapy regimens. NCCN recommended with various chemotherapy combinations. (2) for adjuvant treatment with chemotherapy and as a single agent following multi-modality anthracycline based therapy. (3) Also NCCN recommended for neoadjuvant treatment. |
Gastric Carcinoma -
Malignant Esophageal Neoplasm -
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN-recommended with or without docetaxel for HER2+ salivary gland tumors. |
Trastuzumab/hyaluronidase +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab in any regimen. |
Abemaciclib + Aromatase Inhibitor +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. |
Abemaciclib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Ado-Trastuzumab Emtansine + Endocrine Therapy +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer. |
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: PIK3CA E545Q, PIK3CA Q546K, PIK3CA Q546P, PIK3CA E365K, PIK3CA E453K, PIK3CA G1049R, PIK3CA G106V, PIK3CA G118D, PIK3CA K111E, PIK3CA K111N, PIK3CA M1043I, PIK3CA M1043V, PIK3CA N345K, PIK3CA P447_L455del, PIK3CA P539R, PIK3CA R108H, PIK3CA R88Q, PIK3CA R93W, PIK3CA T1025A, PIK3CA V344G, PIK3CA V344M Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative, PIK3CA-mutated, recurrent or metastatic breast cancer. |
Anastrozole + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as first line therapy. |
Aromatase Inhibitor + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved with letrozole as the aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. NCCN recommended for any aromatase inhibitor. |
Aromatase Inhibitor + Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positve/HER2-positive recurrent or metastastic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in postmenopausal women or in men. |
Aromatase Inhibitor + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. |
Aromatase Inhibitor + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Atezolizumab + Nab-Paclitaxel +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area. |
Capecitabine + Cisplatin + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Capecitabine + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for advanced or metastatic breast cancer that overexpresses HER2 and that had prior therapy including an anthracycline, a taxane, and trastuzumab. |
Capecitabine + Trastuzumab + Tucatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for patients with advanced HER2-positive breast cancer that is unresectable or metastatic, who have received one or more prior treatments. |
Carboplatin + Docetaxel + Trastuzumab +
Cisplatin + Fluorouracil + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Docetaxel + Trastuzumab +
Endocrine Therapy + Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer, with or without chemotherapy. |
Endocrine Therapy + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) | |
| Note: Recommend for HR-positive/HER2-positive breast cancer, with fulvestrant, tamoxifen, or aromatase inhibitor metastastic disease, or with tamoxifen or aromatase inhibitor for adjuvant treatment. |
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with advanced HR+, HER2- breast cancer after failure of treatment with letrozole or anastrozole. |
Everolimus + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as subsequent line therapy. |
Everolimus + Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as subsequent line therapy. |
Fulvestrant + Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as first line therapy. |
Fulvestrant + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Fulvestrant + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy, or following disease progression on endocrine therapy. |
Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommened for recurrent or metastatic HER2-positive breast cancer, without cytotoxic therapy. |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) |
Paclitaxel + Pertuzumab + Trastuzumab +
Paclitaxel + Trastuzumab +
Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: FDA approved for HER2-positive breast cancer, for metastatic disease with paclitaxel for with no prior anti-HER2 therapy or chemotherapy in that setting, and for adjuvant and neoadjuvant treatment in combination with chemotherapy. Per NCCN, other chemotherapy combinations, or no chemotherapy combination, are options for these settings. |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) |
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN-recommended for HER2+ salivary gland tumors. |
Clinical Trials
ERBB2 status serves as an inclusion eligibility criteria in 1323 clinical trials, of which 988 are open and 335 are closed. Of the trials that contain ERBB2 status as an inclusion criterion, 24 are early phase 1 (17 open), 360 are phase 1 (241 open), 204 are phase 1/phase 2 (154 open), 535 are phase 2 (414 open), 17 are phase 2/phase 3 (13 open), 141 are phase 3 (117 open), 6 are phase 4 (2 open), and 36 are no phase specified (30 open).
Trials with ERBB2 status in the inclusion eligibility criteria most commonly target breast carcinoma, malignant solid tumor, invasive breast carcinoma, adenocarcinoma of the gastroesophageal junction, and breast adenocarcinoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are ERBB2 Loss and ERBB2 Amplification [4].
Trastuzumab, paclitaxel, pembrolizumab, cyclophosphamide, and fulvestrant are the most frequent therapies in trials with ERBB2 as an inclusion criteria [4].
Significance of ERBB2 in Diseases
Breast Carcinoma +
ERBB2 is altered in 13.78% of breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 1034 clinical trials for breast carcinoma, of which 743 are open and 291 are closed. Of the trials that contain ERBB2 status and breast carcinoma as inclusion criteria, 18 are early phase 1 (12 open), 297 are phase 1 (191 open), 170 are phase 1/phase 2 (127 open), 397 are phase 2 (291 open), 11 are phase 2/phase 3 (8 open), 109 are phase 3 (90 open), 6 are phase 4 (2 open), and 26 are no phase specified (22 open) [4].
Everolimus, exemestane, ado-trastuzumab emtansine, alpelisib, fulvestrant, aromatase inhibitor, trastuzumab, sacituzumab govitecan, letrozole, palbociclib, ribociclib, lapatinib, margetuximab, neratinib, paclitaxel, pertuzumab, tamoxifen, pembrolizumab, pertuzumab/trastuzumab/hyaluronidase, fam-trastuzumab deruxtecan, abemaciclib, endocrine therapy, anastrozole, atezolizumab, nab-paclitaxel, capecitabine, tucatinib, carboplatin, docetaxel, and trastuzumab/hyaluronidase have evidence of efficacy in patients with ERBB2 mutation in breast carcinoma [4].
Non-Small Cell Lung Carcinoma +
ERBB2 is altered in 3.97% of non-small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 126 clinical trials for non-small cell lung carcinoma, of which 86 are open and 40 are closed. Of the trials that contain ERBB2 status and non-small cell lung carcinoma as inclusion criteria, 59 are phase 1 (32 open), 34 are phase 1/phase 2 (25 open), and 33 are phase 2 (29 open) [4].
Ado-trastuzumab emtansine has evidence of efficacy in patients with ERBB2 mutation in non-small cell lung carcinoma [4].
Adenocarcinoma Of The Gastroesophageal Junction +
ERBB2 is altered in 19.62% of adenocarcinoma of the gastroesophageal junction patients [3].
ERBB2 is an inclusion criterion in 74 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 55 are open and 19 are closed. Of the trials that contain ERBB2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 21 are phase 1 (14 open), 13 are phase 1/phase 2 (10 open), 24 are phase 2 (21 open), 4 are phase 2/phase 3 (3 open), 11 are phase 3 (7 open), and 1 is no phase specified (0 open) [4].
Capecitabine, cisplatin, trastuzumab, and fluorouracil have evidence of efficacy in patients with ERBB2 mutation in adenocarcinoma of the gastroesophageal junction [4].
Colorectal Carcinoma +
ERBB2 is altered in 4.69% of colorectal carcinoma patients [3].
ERBB2 is an inclusion criterion in 70 clinical trials for colorectal carcinoma, of which 51 are open and 19 are closed. Of the trials that contain ERBB2 status and colorectal carcinoma as inclusion criteria, 42 are phase 1 (29 open), 20 are phase 1/phase 2 (15 open), and 8 are phase 2 (7 open) [4].
Lapatinib, trastuzumab, and pertuzumab have evidence of efficacy in patients with ERBB2 mutation in colorectal carcinoma [4].
Gastric Carcinoma +
ERBB2 is altered in 10.1% of gastric carcinoma patients [3].
ERBB2 is an inclusion criterion in 66 clinical trials for gastric carcinoma, of which 36 are open and 30 are closed. Of the trials that contain ERBB2 status and gastric carcinoma as inclusion criteria, 31 are phase 1 (13 open), 17 are phase 1/phase 2 (12 open), 14 are phase 2 (10 open), 1 is phase 2/phase 3 (0 open), and 3 are phase 3 (1 open) [4].
Capecitabine, cisplatin, trastuzumab, and fluorouracil have evidence of efficacy in patients with ERBB2 mutation in gastric carcinoma [4].
Malignant Salivary Gland Neoplasm +
ERBB2 is altered in 6.96% of malignant salivary gland neoplasm patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for malignant salivary gland neoplasm, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant salivary gland neoplasm as inclusion criteria, 3 are phase 2 (3 open) [4].
Ado-trastuzumab emtansine, pertuzumab, and trastuzumab have evidence of efficacy in patients with ERBB2 mutation in malignant salivary gland neoplasm [4].
Malignant Solid Tumor +
ERBB2 is altered in 5.44% of malignant solid tumor patients [3].
ERBB2 is an inclusion criterion in 213 clinical trials for malignant solid tumor, of which 149 are open and 64 are closed. Of the trials that contain ERBB2 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 131 are phase 1 (84 open), 56 are phase 1/phase 2 (42 open), and 25 are phase 2 (22 open) [4].
Ovarian Carcinoma +
ERBB2 is altered in 3.28% of ovarian carcinoma patients [3].
ERBB2 is an inclusion criterion in 86 clinical trials for ovarian carcinoma, of which 57 are open and 29 are closed. Of the trials that contain ERBB2 status and ovarian carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 51 are phase 1 (27 open), 24 are phase 1/phase 2 (19 open), and 10 are phase 2 (10 open) [4].
Invasive Breast Carcinoma +
ERBB2 is altered in 13.88% of invasive breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 60 clinical trials for invasive breast carcinoma, of which 59 are open and 1 is closed. Of the trials that contain ERBB2 status and invasive breast carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 7 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), 38 are phase 2 (37 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (7 open), and 2 are no phase specified (2 open) [4].
Gastric Adenocarcinoma +
ERBB2 is altered in 10.08% of gastric adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 59 clinical trials for gastric adenocarcinoma, of which 49 are open and 10 are closed. Of the trials that contain ERBB2 status and gastric adenocarcinoma as inclusion criteria, 13 are phase 1 (10 open), 12 are phase 1/phase 2 (11 open), 21 are phase 2 (18 open), 3 are phase 2/phase 3 (3 open), 9 are phase 3 (7 open), and 1 is no phase specified (0 open) [4].
Breast Adenocarcinoma +
ERBB2 is altered in 13.55% of breast adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 53 clinical trials for breast adenocarcinoma, of which 49 are open and 4 are closed. Of the trials that contain ERBB2 status and breast adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (12 open), 5 are phase 1/phase 2 (4 open), 22 are phase 2 (20 open), 1 is phase 2/phase 3 (1 open), 10 are phase 3 (9 open), and 2 are no phase specified (2 open) [4].
Head And Neck Squamous Cell Carcinoma +
ERBB2 is altered in 2.81% of head and neck squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 51 clinical trials for head and neck squamous cell carcinoma, of which 34 are open and 17 are closed. Of the trials that contain ERBB2 status and head and neck squamous cell carcinoma as inclusion criteria, 28 are phase 1 (16 open), 18 are phase 1/phase 2 (15 open), and 5 are phase 2 (3 open) [4].
Melanoma +
ERBB2 is altered in 3.29% of melanoma patients [3].
ERBB2 is an inclusion criterion in 46 clinical trials for melanoma, of which 28 are open and 18 are closed. Of the trials that contain ERBB2 status and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 26 are phase 1 (15 open), 8 are phase 1/phase 2 (5 open), and 11 are phase 2 (8 open) [4].
Pancreatic Carcinoma +
ERBB2 is altered in 2.14% of pancreatic carcinoma patients [3].
ERBB2 is an inclusion criterion in 39 clinical trials for pancreatic carcinoma, of which 30 are open and 9 are closed. Of the trials that contain ERBB2 status and pancreatic carcinoma as inclusion criteria, 21 are phase 1 (14 open), 11 are phase 1/phase 2 (9 open), and 7 are phase 2 (7 open) [4].
Urothelial Carcinoma +
ERBB2 is altered in 14.87% of urothelial carcinoma patients [3].
ERBB2 is an inclusion criterion in 38 clinical trials for urothelial carcinoma, of which 27 are open and 11 are closed. Of the trials that contain ERBB2 status and urothelial carcinoma as inclusion criteria, 18 are phase 1 (10 open), 14 are phase 1/phase 2 (12 open), and 6 are phase 2 (5 open) [4].
Endometrial Carcinoma +
ERBB2 is altered in 8.93% of endometrial carcinoma patients [3].
ERBB2 is an inclusion criterion in 35 clinical trials for endometrial carcinoma, of which 29 are open and 6 are closed. Of the trials that contain ERBB2 status and endometrial carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 16 are phase 1 (13 open), 12 are phase 1/phase 2 (9 open), and 6 are phase 2 (6 open) [4].
Renal Cell Carcinoma +
ERBB2 is altered in 1.11% of renal cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 34 clinical trials for renal cell carcinoma, of which 22 are open and 12 are closed. Of the trials that contain ERBB2 status and renal cell carcinoma as inclusion criteria, 20 are phase 1 (10 open), 9 are phase 1/phase 2 (8 open), and 5 are phase 2 (4 open) [4].
Fallopian Tube Carcinoma +
ERBB2 is an inclusion criterion in 34 clinical trials for fallopian tube carcinoma, of which 22 are open and 12 are closed. Of the trials that contain ERBB2 status and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 22 are phase 1 (11 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [4].
Small Cell Lung Carcinoma +
ERBB2 is altered in 2.64% of small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 33 clinical trials for small cell lung carcinoma, of which 25 are open and 8 are closed. Of the trials that contain ERBB2 status and small cell lung carcinoma as inclusion criteria, 15 are phase 1 (10 open), 13 are phase 1/phase 2 (10 open), and 5 are phase 2 (5 open) [4].
Prostate Carcinoma +
ERBB2 is altered in 1.14% of prostate carcinoma patients [3].
ERBB2 is an inclusion criterion in 33 clinical trials for prostate carcinoma, of which 23 are open and 10 are closed. Of the trials that contain ERBB2 status and prostate carcinoma as inclusion criteria, 21 are phase 1 (12 open), 7 are phase 1/phase 2 (6 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].
Primary Peritoneal Carcinoma +
ERBB2 is altered in 8.7% of primary peritoneal carcinoma patients [3].
ERBB2 is an inclusion criterion in 32 clinical trials for primary peritoneal carcinoma, of which 20 are open and 12 are closed. Of the trials that contain ERBB2 status and primary peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 20 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [4].
Esophageal Carcinoma +
ERBB2 is altered in 16.67% of esophageal carcinoma patients [3].
ERBB2 is an inclusion criterion in 28 clinical trials for esophageal carcinoma, of which 17 are open and 11 are closed. Of the trials that contain ERBB2 status and esophageal carcinoma as inclusion criteria, 9 are phase 1 (3 open), 10 are phase 1/phase 2 (8 open), 7 are phase 2 (5 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Bladder Carcinoma +
ERBB2 is altered in 14.96% of bladder carcinoma patients [3].
ERBB2 is an inclusion criterion in 25 clinical trials for bladder carcinoma, of which 16 are open and 9 are closed. Of the trials that contain ERBB2 status and bladder carcinoma as inclusion criteria, 13 are phase 1 (5 open), 5 are phase 1/phase 2 (4 open), and 7 are phase 2 (7 open) [4].
Hepatocellular Carcinoma +
ERBB2 is altered in 0.23% of hepatocellular carcinoma patients [3].
ERBB2 is an inclusion criterion in 23 clinical trials for hepatocellular carcinoma, of which 19 are open and 4 are closed. Of the trials that contain ERBB2 status and hepatocellular carcinoma as inclusion criteria, 13 are phase 1 (10 open), 8 are phase 1/phase 2 (7 open), and 2 are phase 2 (2 open) [4].
Cervical Carcinoma +
ERBB2 is altered in 9.09% of cervical carcinoma patients [3].
ERBB2 is an inclusion criterion in 22 clinical trials for cervical carcinoma, of which 18 are open and 4 are closed. Of the trials that contain ERBB2 status and cervical carcinoma as inclusion criteria, 14 are phase 1 (11 open), 6 are phase 1/phase 2 (5 open), and 2 are phase 2 (2 open) [4].
Esophageal Adenocarcinoma +
ERBB2 is altered in 19.0% of esophageal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 15 clinical trials for esophageal adenocarcinoma, of which 15 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), 8 are phase 2 (8 open), and 1 is phase 3 (1 open) [4].
Pancreatic Adenocarcinoma +
ERBB2 is altered in 2.15% of pancreatic adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 15 clinical trials for pancreatic adenocarcinoma, of which 10 are open and 5 are closed. Of the trials that contain ERBB2 status and pancreatic adenocarcinoma as inclusion criteria, 7 are phase 1 (5 open), 7 are phase 1/phase 2 (4 open), and 1 is phase 2 (1 open) [4].
Head And Neck Carcinoma +
ERBB2 is altered in 4.04% of head and neck carcinoma patients [3].
ERBB2 is an inclusion criterion in 14 clinical trials for head and neck carcinoma, of which 9 are open and 5 are closed. Of the trials that contain ERBB2 status and head and neck carcinoma as inclusion criteria, 10 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].
Soft Tissue Sarcoma +
ERBB2 is altered in 0.91% of soft tissue sarcoma patients [3].
ERBB2 is an inclusion criterion in 14 clinical trials for soft tissue sarcoma, of which 9 are open and 5 are closed. Of the trials that contain ERBB2 status and soft tissue sarcoma as inclusion criteria, 8 are phase 1 (3 open), 5 are phase 1/phase 2 (5 open), and 1 is phase 2 (1 open) [4].
Squamous Cell Lung Carcinoma +
ERBB2 is altered in 2.04% of squamous cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 13 clinical trials for squamous cell lung carcinoma, of which 11 are open and 2 are closed. Of the trials that contain ERBB2 status and squamous cell lung carcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].
Ductal Carcinoma In Situ +
ERBB2 is altered in 3.08% of ductal carcinoma in situ patients [3].
ERBB2 is an inclusion criterion in 12 clinical trials for ductal carcinoma in situ, of which 10 are open and 2 are closed. Of the trials that contain ERBB2 status and ductal carcinoma in situ as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 2 are no phase specified (2 open) [4].
Glioblastoma +
ERBB2 is altered in 1.84% of glioblastoma patients [3].
ERBB2 is an inclusion criterion in 10 clinical trials for glioblastoma, of which 6 are open and 4 are closed. Of the trials that contain ERBB2 status and glioblastoma as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Inflammatory Breast Carcinoma +
ERBB2 is altered in 21.43% of inflammatory breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 9 clinical trials for inflammatory breast carcinoma, of which 9 are open and 0 are closed. Of the trials that contain ERBB2 status and inflammatory breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].
Breast Invasive Ductal Carcinoma +
ERBB2 is altered in 14.14% of breast invasive ductal carcinoma patients [3].
ERBB2 is an inclusion criterion in 9 clinical trials for breast invasive ductal carcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERBB2 status and breast invasive ductal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), 2 are phase 3 (2 open), and 3 are no phase specified (2 open) [4].
Colorectal Adenocarcinoma +
ERBB2 is altered in 4.69% of colorectal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 9 clinical trials for colorectal adenocarcinoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [4].
Pancreatic Ductal Adenocarcinoma +
ERBB2 is an inclusion criterion in 9 clinical trials for pancreatic ductal adenocarcinoma, of which 5 are open and 4 are closed. Of the trials that contain ERBB2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].
Mesothelioma +
ERBB2 is an inclusion criterion in 8 clinical trials for mesothelioma, of which 5 are open and 3 are closed. Of the trials that contain ERBB2 status and mesothelioma as inclusion criteria, 8 are phase 1 (5 open) [4].
Cancer +
ERBB2 is altered in 5.14% of cancer patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for cancer, of which 3 are open and 4 are closed. Of the trials that contain ERBB2 status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].
Cholangiocarcinoma +
ERBB2 is altered in 4.07% of cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for cholangiocarcinoma, of which 5 are open and 2 are closed. Of the trials that contain ERBB2 status and cholangiocarcinoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Prostate Adenocarcinoma +
ERBB2 is altered in 1.09% of prostate adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 7 clinical trials for prostate adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 status and prostate adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open) and 4 are phase 1/phase 2 (3 open) [4].
Nasopharyngeal Carcinoma +
ERBB2 is an inclusion criterion in 7 clinical trials for nasopharyngeal carcinoma, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 status and nasopharyngeal carcinoma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Gallbladder Carcinoma +
ERBB2 is altered in 10.45% of gallbladder carcinoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for gallbladder carcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and gallbladder carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].
Esophageal Squamous Cell Carcinoma +
ERBB2 is altered in 4.73% of esophageal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for esophageal squamous cell carcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
Non-Hodgkin Lymphoma +
ERBB2 is altered in 1.49% of non-hodgkin lymphoma patients [3].
ERBB2 is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 status and non-hodgkin lymphoma as inclusion criteria, 4 are phase 1 (4 open) and 2 are phase 2 (2 open) [4].
Esophagogastric Carcinoma +
ERBB2 is altered in 14.54% of esophagogastric carcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for esophagogastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and esophagogastric carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [4].
Lung Adenocarcinoma +
ERBB2 is altered in 4.32% of lung adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for lung adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Biliary Tract Carcinoma +
ERBB2 is altered in 5.41% of biliary tract carcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for biliary tract carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and biliary tract carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 2 (3 open) [4].
Malignant Ovarian Epithelial Tumor +
ERBB2 is altered in 3.41% of malignant ovarian epithelial tumor patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for malignant ovarian epithelial tumor, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
ERBB2 is altered in 2.91% of high grade ovarian serous adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for high grade ovarian serous adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [4].
Merkel Cell Carcinoma +
ERBB2 is altered in 0.85% of Merkel cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for Merkel cell carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [4].
Multiple Myeloma +
ERBB2 is altered in 0.83% of multiple myeloma patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Acute Myeloid Leukemia +
ERBB2 is altered in 0.45% of acute myeloid leukemia patients [3].
ERBB2 is an inclusion criterion in 5 clinical trials for acute myeloid leukemia, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [4].
Peritoneal Mesothelioma +
ERBB2 is an inclusion criterion in 5 clinical trials for peritoneal mesothelioma, of which 2 are open and 3 are closed. Of the trials that contain ERBB2 status and peritoneal mesothelioma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
ERBB2 is altered in 4.28% of non-squamous non-small cell lung carcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for non-squamous non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
ERBB2 is altered in 3.6% of oropharyngeal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for oropharyngeal squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [4].
Diffuse Large B-Cell Lymphoma +
ERBB2 is altered in 2.83% of diffuse large B-cell lymphoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain ERBB2 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Clear Cell Renal Cell Carcinoma +
ERBB2 is altered in 1.28% of clear cell renal cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain ERBB2 status and clear cell renal cell carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Thymic Carcinoma +
ERBB2 is altered in 1.03% of thymic carcinoma patients [3].
ERBB2 is an inclusion criterion in 4 clinical trials for thymic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 status and thymic carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].
Chronic Lymphocytic Leukemia +
ERBB2 is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain ERBB2 status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].
Breast Invasive Lobular Carcinoma +
ERBB2 is altered in 12.05% of breast invasive lobular carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for breast invasive lobular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Skin Squamous Cell Carcinoma +
ERBB2 is altered in 5.83% of skin squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for skin squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].
Malignant Uterine Neoplasm +
ERBB2 is altered in 8.03% of malignant uterine neoplasm patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for malignant uterine neoplasm, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Colon Carcinoma +
ERBB2 is altered in 5.2% of colon carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and colon carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Cutaneous Melanoma +
ERBB2 is altered in 4.05% of cutaneous melanoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for cutaneous melanoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Laryngeal Squamous Cell Carcinoma +
ERBB2 is altered in 2.35% of laryngeal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for laryngeal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Intrahepatic Cholangiocarcinoma +
ERBB2 is altered in 2.89% of intrahepatic cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for intrahepatic cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
B-Cell Non-Hodgkin Lymphoma +
ERBB2 is altered in 1.62% of B-cell non-hodgkin lymphoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].
Hematopoietic And Lymphoid Malignancy +
ERBB2 is altered in 0.87% of hematopoietic and lymphoid malignancy patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for hematopoietic and lymphoid malignancy, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Mantle Cell Lymphoma +
ERBB2 is altered in 0.56% of mantle cell lymphoma patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].
Gastrointestinal Stromal Tumor +
ERBB2 is altered in 0.54% of gastrointestinal stromal tumor patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Myelodysplastic Syndromes +
ERBB2 is altered in 0.41% of myelodysplastic syndromes patients [3].
ERBB2 is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].
Breast Lobular Carcinoma In Situ +
ERBB2 is an inclusion criterion in 3 clinical trials for breast lobular carcinoma in situ, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and breast lobular carcinoma in situ as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (1 open) [4].
Classical Hodgkin Lymphoma +
ERBB2 is an inclusion criterion in 3 clinical trials for classical hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and classical hodgkin lymphoma as inclusion criteria, 3 are phase 1/phase 2 (3 open) [4].
High Grade Fallopian Tube Serous Adenocarcinoma +
ERBB2 is an inclusion criterion in 3 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Hypopharyngeal Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 3 clinical trials for hypopharyngeal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Malignant Pleural Mesothelioma +
ERBB2 is an inclusion criterion in 3 clinical trials for malignant pleural mesothelioma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant pleural mesothelioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Pleural Mesothelioma +
ERBB2 is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 0 are open and 3 are closed. Of the trials that contain ERBB2 status and pleural mesothelioma as inclusion criteria, 3 are phase 1 (0 open) [4].
Small Intestinal Adenocarcinoma +
ERBB2 is altered in 12.73% of small intestinal adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for small intestinal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and small intestinal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].
Endometrial Serous Adenocarcinoma +
ERBB2 is altered in 11.17% of endometrial serous adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for endometrial serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and endometrial serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Primary Peritoneal Serous Adenocarcinoma +
ERBB2 is altered in 8.7% of primary peritoneal serous adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Lobular Breast Carcinoma +
ERBB2 is altered in 11.97% of lobular breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for lobular breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and lobular breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Uterine Corpus Carcinosarcoma +
ERBB2 is altered in 7.17% of uterine corpus carcinosarcoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for uterine corpus carcinosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Salivary Gland Carcinoma +
ERBB2 is altered in 6.96% of salivary gland carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for salivary gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and salivary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Endometrial Endometrioid Adenocarcinoma +
ERBB2 is altered in 7.66% of endometrial endometrioid adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Mixed Lobular And Ductal Breast Carcinoma +
ERBB2 is altered in 9.77% of mixed lobular and ductal breast carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for mixed lobular and ductal breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Extrahepatic Cholangiocarcinoma +
ERBB2 is altered in 8.97% of extrahepatic cholangiocarcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for extrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and extrahepatic cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Malignant Ovarian Clear Cell Tumor +
ERBB2 is altered in 5.45% of malignant ovarian clear cell tumor patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for malignant ovarian clear cell tumor, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Cervical Squamous Cell Carcinoma +
ERBB2 is altered in 6.22% of cervical squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and cervical squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Neuroendocrine Carcinoma +
ERBB2 is altered in 2.98% of neuroendocrine carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for neuroendocrine carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and neuroendocrine carcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Oropharyngeal Carcinoma +
ERBB2 is altered in 3.6% of oropharyngeal carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for oropharyngeal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and oropharyngeal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Oral Cavity Squamous Cell Carcinoma +
ERBB2 is altered in 2.42% of oral cavity squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for oral cavity squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and oral cavity squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Malignant Glioma +
ERBB2 is altered in 1.71% of malignant glioma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for malignant glioma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Central Nervous System Neoplasm +
ERBB2 is altered in 1.37% of central nervous system neoplasm patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and central nervous system neoplasm as inclusion criteria, 2 are phase 1 (2 open) [4].
Kidney Carcinoma +
ERBB2 is altered in 1.14% of kidney carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for kidney carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and kidney carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Liposarcoma +
ERBB2 is altered in 0.99% of liposarcoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Adenoid Cystic Carcinoma +
ERBB2 is altered in 1.32% of adenoid cystic carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for adenoid cystic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and adenoid cystic carcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Thyroid Gland Carcinoma +
ERBB2 is altered in 0.8% of thyroid gland carcinoma patients [3].
ERBB2 is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Acute Lymphoblastic Leukemia +
ERBB2 is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Anal Canal Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 2 clinical trials for anal canal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Ependymoma +
ERBB2 is an inclusion criterion in 2 clinical trials for ependymoma, of which 0 are open and 2 are closed. Of the trials that contain ERBB2 status and ependymoma as inclusion criteria, 2 are phase 1/phase 2 (0 open) [4].
Fallopian Tube Endometrioid Adenocarcinoma +
ERBB2 is an inclusion criterion in 2 clinical trials for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Salivary Duct Carcinoma +
ERBB2 is altered in 29.75% of salivary duct carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Adenocarcinoma +
ERBB2 is altered in 18.57% of salivary gland adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bladder Urothelial Carcinoma +
ERBB2 is altered in 15.57% of bladder urothelial carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Transitional Cell Carcinoma +
ERBB2 is altered in 14.87% of transitional cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Salivary Carcinoma, NOS +
ERBB2 is altered in 11.11% of salivary carcinoma, NOS patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary carcinoma, NOS as inclusion criteria, 1 is phase 2 (1 open) [4].
Small Intestinal Carcinoma +
ERBB2 is altered in 11.18% of small intestinal carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Endometrial Mixed Adenocarcinoma +
ERBB2 is altered in 15.09% of endometrial mixed adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for endometrial mixed adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Renal Pelvis And Ureter Carcinoma +
ERBB2 is altered in 11.89% of renal pelvis and ureter carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ovarian Endometrioid Adenocarcinoma +
ERBB2 is altered in 8.21% of ovarian endometrioid adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Ampulla Of Vater Carcinoma +
ERBB2 is altered in 7.94% of ampulla of vater carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Mixed Mesodermal (Mullerian) Tumor +
ERBB2 is altered in 5.9% of malignant mixed mesodermal (mullerian) tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [4].
Malignant Endometrial Neoplasm +
ERBB2 is altered in 8.72% of malignant endometrial neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant endometrial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant endometrial neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Endometrial Adenocarcinoma +
ERBB2 is altered in 9.01% of endometrial adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Malignant Urethral Neoplasm +
ERBB2 is altered in 7.78% of malignant urethral neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant urethral neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant urethral neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Primary Mediastinal B-Cell Lymphoma +
ERBB2 is altered in 5.56% of primary mediastinal B-cell lymphoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Gastric Diffuse Adenocarcinoma +
ERBB2 is altered in 4.72% of gastric diffuse adenocarcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastric diffuse adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Ovarian Endometrioid Tumor +
ERBB2 is altered in 5.54% of malignant ovarian endometrioid tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].
Ovarian Endometrioid Tumor +
ERBB2 is altered in 5.51% of ovarian endometrioid tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Anal Squamous Cell Carcinoma +
ERBB2 is altered in 4.12% of anal squamous cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Digestive System Carcinoma +
ERBB2 is altered in 6.32% of digestive system carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for digestive system carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and digestive system carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Colorectal Neoplasm +
ERBB2 is altered in 4.69% of malignant colorectal neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant colorectal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant colorectal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Biliary Tract Neoplasm +
ERBB2 is altered in 5.4% of biliary tract neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Digestive System Neoplasm +
ERBB2 is altered in 5.64% of malignant digestive system neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant digestive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant digestive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Laryngeal Neoplasm +
ERBB2 is altered in 2.35% of malignant laryngeal neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Acinic Cell Carcinoma +
ERBB2 is altered in 2.86% of salivary gland acinic cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland acinic cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland acinic cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Hepatobiliary Neoplasm +
ERBB2 is altered in 4.02% of malignant hepatobiliary neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
ERBB2 is altered in 2.11% of thyroid gland undifferentiated (anaplastic) carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Primitive Neuroectodermal Tumor +
ERBB2 is altered in 2.37% of primitive neuroectodermal tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Pancreatic Neuroendocrine Neoplasm +
ERBB2 is altered in 2.02% of pancreatic neuroendocrine neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Lip And Oral Cavity Carcinoma +
ERBB2 is altered in 2.42% of lip and oral cavity carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ovarian Epithelial Tumor +
ERBB2 is altered in 3.48% of ovarian epithelial tumor patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Malignant Ovarian Neoplasm +
ERBB2 is altered in 3.38% of malignant ovarian neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant ovarian neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
ERBB2 is altered in 1.41% of nasal cavity and paranasal sinus carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Cutaneous T Cell Non-Hodgkin Lymphoma +
ERBB2 is altered in 1.01% of primary cutaneous T cell non-hodgkin lymphoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for primary cutaneous T cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and primary cutaneous T cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Hematologic And Lymphocytic Disorder +
ERBB2 is altered in 1.08% of hematologic and lymphocytic disorder patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].
Undifferentiated Pleomorphic Sarcoma +
ERBB2 is altered in 1.26% of undifferentiated pleomorphic sarcoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Thyroid Gland Neoplasm +
ERBB2 is altered in 0.8% of malignant thyroid gland neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Papillary Renal Cell Carcinoma +
ERBB2 is altered in 0.68% of papillary renal cell carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Hematopoietic And Lymphoid System Neoplasm +
ERBB2 is altered in 0.8% of hematopoietic and lymphoid system neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Well-Differentiated Thyroid Gland Carcinoma +
ERBB2 is altered in 0.77% of well-differentiated thyroid gland carcinoma patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for well-differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and well-differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Bone Marrow Neoplasm +
ERBB2 is altered in 0.55% of malignant bone marrow neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for malignant bone marrow neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant bone marrow neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
T-Cell And NK-Cell Neoplasm +
ERBB2 is altered in 0.62% of T-cell and NK-cell neoplasm patients [3].
ERBB2 is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Aggressive Systemic Mastocytosis +
ERBB2 is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].
Benign Breast Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and benign breast neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Bilateral Breast Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for bilateral breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and bilateral breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bronchogenic Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Cervical Carcinosarcoma +
ERBB2 is an inclusion criterion in 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and cervical carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Chondrosarcoma +
ERBB2 is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Chordoma +
ERBB2 is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and chordoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Desmoid-Type Fibromatosis +
ERBB2 is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Diffuse Intrinsic Pontine Glioma +
ERBB2 is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Diffuse Midline Glioma, H3 K27M-Mutant +
ERBB2 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [4].
Esophageal Adenosquamous Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for esophageal adenosquamous carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and esophageal adenosquamous carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Fallopian Tube Clear Cell Adenocarcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Gastric Adenosquamous Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for gastric adenosquamous carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastric adenosquamous carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gastric Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gliosarcoma +
ERBB2 is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Histiocytic And Dendritic Cell Neoplasm +
ERBB2 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Hypopharyngeal Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Kaposi Sarcoma +
ERBB2 is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Mast Cell Leukemia +
ERBB2 is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Medullary Breast Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for medullary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and medullary breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Metastatic Malignant Neoplasm In The Brain +
ERBB2 is an inclusion criterion in 1 clinical trial for metastatic malignant neoplasm in the brain, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and metastatic malignant neoplasm in the brain as inclusion criteria, 1 is phase 2 (0 open) [4].
NUT Midline Carcinoma Of The Head And Neck +
ERBB2 is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [4].
Penile Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Primary Peritoneal Carcinosarcoma +
ERBB2 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Prostate Undifferentiated Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Salivary Gland Carcinoma Ex Pleomorphic Adenoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland carcinoma ex pleomorphic adenoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland carcinoma ex pleomorphic adenoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Mucoepidermoid Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland mucoepidermoid carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland mucoepidermoid carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Small Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland small cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Squamous Cell Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for salivary gland squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Squamous Cell Carcinoma Of The Penis +
ERBB2 is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 1 (1 open) [4].
Systemic Mastocytosis With An Associated Hematological Neoplasm (SM-AHN) +
ERBB2 is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].
Tenosynovial Giant Cell Tumor +
ERBB2 is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and tenosynovial giant cell tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Tenosynovial Giant Cell Tumor, Diffuse Type +
ERBB2 is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, diffuse type, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and tenosynovial giant cell tumor, diffuse type as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Follicular Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Ureter Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ureter Urothelial Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Uveal Melanoma +
ERBB2 is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Vulvar Carcinoma +
ERBB2 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
